This program is supported by an independent educational grant from Pfizer. This online education program has been designed for healthcare professionals globally.

Join thoracic oncology experts Dr. Urs Weber and Dr. Kyle Concannon for this free, accredited, 60-minute interactive virtual session that bridges the gap between clinical data and the human experience. Moving far beyond standard guideline recaps, this unique masterclass delivers a dual-perspective learning journey—directly charting how high-stakes medical decisions intersect with the real-world anxieties, information overload, and lived realities of patients and their care partners.

Participants will learn tactical, evidence-backed strategies to confidently recognize subtle neurocognitive adverse events, streamline multidisciplinary communication, and master preference-informed shared decision-making in daily practice.

Accreditation: 0.75 AMA PRA Category 1 Credits™

Session Overview

• Preparing Patients and Care Partners for ALK Inhibitor Therapy: This segment covers clinical methods for prioritizing information, setting clear expectations, and assessing patient readiness at treatment initiation. It also addresses how patients and care partners can successfully navigate information overload, uncertainty, and emotional adjustments following their diagnosis.
• Early Recognition of Neurocognitive and Functional Adverse Events: Faculty will demonstrate how to interpret subtle cognitive, mood, and functional shifts to determine timely clinical assessment and escalation. This is paired with insights into the patient experience of noticing treatment-related changes that feel "off" but are highly difficult to articulate or contextualize.
• Activating Early Reporting and Care-Team Communication: Clinicians will learn to establish clear reporting thresholds and structured multidisciplinary communication pathways to minimize reactive case management. Concurrently, the discussion focuses on helping patients and care partners understand what clinical changes matter, when to report them, and exactly who to contact.
• Facilitating Preference-Informed Decision-Making Over Time: The session explores frameworks for regularly revisiting benefit–risk definitions and adapting clinical recommendations as a patient's care journey evolves. It highlights practical ways to capture and respect the patient's changing values, risk tolerance, fatigue, and life priorities over time.

Who Should Attend?

This program is for healthcare professionals worldwide, involved in the diagnosis, treatment selection, and ongoing management of patients with ALK-positive metastatic NSCLC.

• Medical/radiation oncologists, oncology nurses, NPs, PAs
• Pharmacists, registered dietitians, mental health professionals
• Multidisciplinary team members involved in ALK-positive NSCLC care

Faculty

Dr Urs Weber, MD, is an Assistant Professor in the Division of Medical Oncology at the University of Colorado School of Medicine and a practicing clinician at the University of Colorado Cancer Center. He earned his medical degree from the Yale University School of Medicine and completed his hematology/oncology fellowship at the University of Colorado. Dr. Weber specializes in thoracic malignancies, including non-small cell lung cancer (NSCLC), mesothelioma, and rare chest cavity tumors. His research focuses on designing clinical trials, optimizing treatment sequencing, and overcoming resistance mechanisms in oncogene-addicted lung cancers, specifically ALK- and ROS1-rearranged disease.

Dr Kyle Concannon, MD, is an Assistant Professor of Medicine in the Division of Medical Oncology at the University of Colorado School of Medicine and a thoracic medical oncologist at UCHealth University of Colorado Hospital. He completed his physician-scientist training at the MD Anderson Cancer Center before joining the faculty at the University of Colorado. Dr. Concannon's research laboratory focuses on defining why oncogene-driven lung cancers—specifically those with EGFR, HER2, ALK, or ROS1 mutations—develop resistance to therapy and creating innovative strategies to overcome it. In addition to his clinical and translational research work, he co-hosts the Cracking Cancer podcast alongside several patient partners to support and educate the broader lung cancer community.

Continuing Education Information

This continuing education activity will be provided by Current Concepts Institute (CCI) and MedAll. Physicians, Nurse Practitioners, and Physician Assistants will be eligible for AMA PRA Category 1 Credit™; Nurses for ANCC Contact Hours. Pharmacists will be eligible for ACPE credit. A statement of participation is available for other healthcare professionals.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the European Board for Accreditation of Continuing Education for Health Professionals (EBAC)

MedAll is an EBAC accredited provider since 2025. The European Board for Accreditation of Continuing Education for Health Professionals (EBAC) accredits Continuing Education (CE) programmes for the international medical community.

This program is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) for 0.75 hour of effective education time.

EBAC® holds an agreement on mutual recognition of substantive equivalency with the US Accreditation Council for CME (ACCME) and the Royal College of Physicians and Surgeons of Canada, respectively.

Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) and the American Medical Association, physicians may convert EBAC® External CME credits to AMA PRA Category 1 Credits. Information on the process to convert EBAC® credit to AMA credit can be found on the AMA website. Other healthcare professionals may obtain from the AMA a certificate of participation in an activity eligible for conversion of credit to AMA PRA Category 1 Credit.

The Accreditation Council for Continuing Medical Education (ACCME) and the Royal College of Physicians and Surgeons of Canada hold an agreement on substantial equivalency of accreditation systems with EBAC.

EBAC® is a member of the International Academy for CPD Accreditation (IACPDA) and a partner member of the International Association of Medical Regulatory Authorities (IAMRA).

Unapproved and/or off-label use disclosure

Current Concepts Institute/MedAll requires CE faculty to disclose to the participants:

1. When products or procedures being discussed are off-label, unlabelled, experimental, and/or investigational (not US Food and Drug Administration [FDA] approved); and

2. Any limitations on the information presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.

Disclosures

Below is a listing of all individuals who are involved in the planning and implementation of this accredited continuing education activity. All relevant financial relationships listed for these individuals have been mitigated.

Dr Urs Weber, MD has disclosed financial relationships within the past 24 months with the following ineligible companies: Consultant: Boehringer-Ingelheim, BlossomHill, EMD Serono, Johnson&Johnson. Dr Weber does not intend to discuss non-FDA uses of drug products and/or devices.

CCI staff, MedAll staff, and all planners and reviewers have no relevant financial relationships with ineligible companies to disclose.

Activity Accreditation for Health Professions

Physicians

0.75 AMA PRA Category 1 Credits™ are available for this activity.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Current Concepts Institute and MedAll Education. Current Concepts Institute is accredited by the ACCME to provide continuing medical education for physicians.

Current Concepts Institute designates this online activity a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Professionals

All other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.

Participation Costs

There is no cost to participate in this program.

This continuing education activity is active starting 29th July 2026 and will expire on 29th July 2026. Estimated time to complete this activity: 60 minutes.